Selank is a synthetic heptapeptide analog of tuftsin (sequence TKPRPGP), stabilized with a C-terminal Pro-Gly-Pro extension. Research studies it for GABAergic and regulatory signaling. It is a laboratory research compound and is not for human use.

What is the reported mechanism of Selank?

The literature centers on GABAergic and regulatory signaling, with reported effects on the expression of GABA-related and neurotrophic genes. This regulatory emphasis distinguishes it from Semax's neurotrophic focus. The work is preclinical and does not demonstrate outcomes in people.

How is Selank different from Semax?

Both are Pro-Gly-Pro-stabilized heptapeptide analogs, but Selank (from tuftsin) is studied for GABAergic/regulatory signaling, while Semax (from an ACTH fragment) is studied for neurotrophic/BDNF activity. They act on different pathways and are studied as complementary research tools.

Compound Profile2 min readUpdated May 27, 2026

On this page

What is Selank?
What does the research literature study?
How it relates to Semax
Handling and storage
Sources and further reading

Selank: Compound Profile

Selank is the regulatory member of the nootropic-neuropeptide class, the counterpart to the neurotrophic-leaning Semax. This profile covers its identity, the mechanism the literature attributes to it, and how it relates to Semax. For the class, see the neuropeptides overview.

What is Selank?#

Selank is a synthetic peptide modeled on tuftsin, a naturally occurring immunomodulatory tetrapeptide, with a Pro-Gly-Pro extension added at the C-terminus for stability. It was developed in Russia and is studied for regulatory and GABAergic signaling rather than the neurotrophic emphasis of its class-mate Semax.

Attribute	Value
Common name	Selank
Class	Synthetic tuftsin analog; heptapeptide
Sequence	Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP)
CAS number	129954-34-3
Stabilizing feature	C-terminal Pro-Gly-Pro extension
Primary study area	GABAergic / regulatory and anxiolytic-pathway research

Selank molecular identity, as commonly reported in the literature and chemical databases.

Two-dimensional structure of Selank, a tuftsin heptapeptide with a Pro-Gly-Pro extension. Surgical-green heteroatoms (N, O) over a white skeleton on a dark background. — Selank · tuftsin heptapeptide with a Pro-Gly-Pro extension · structure rendered from PubChem CID 11765600 via RDKit.

What does the research literature study?#

Selank is studied for its effects on GABAergic and regulatory signaling, which is the basis for its appearance in anxiolytic-pathway research. The literature also reports effects on the expression of GABA-related and neurotrophic genes. As a tuftsin analog it carries a regulatory rather than neurotrophic emphasis. This is preclinical and pharmacology research; it does not establish anxiety or other outcomes in people.

How it relates to Semax#

Selank leans regulatory (GABAergic signaling); Semax leans neurotrophic (BDNF pathway). The two share a Pro-Gly-Pro-stabilized design but act on different pathways, which is why the literature studies them as a complementary pair. The full breakdown is in Semax vs Selank.

Handling and storage#

Selank is provided lyophilized and reconstituted before use. As a short stabilized peptide it is reasonably robust, but storage follows standard catalog practice: the reconstitution primer covers solvent choice, and the cold-chain article covers stability once reconstituted.

Nexara catalogs Selank (10mg) at ≥99% purity for laboratory research. Independent third-party COA delivery is paused during the transition to a new testing laboratory; see research compliance.

Frequently asked

What is Selank?: Selank is a synthetic heptapeptide analog of tuftsin (sequence TKPRPGP), stabilized with a C-terminal Pro-Gly-Pro extension. Research studies it for GABAergic and regulatory signaling. It is a laboratory research compound and is not for human use.
What is the reported mechanism of Selank?: The literature centers on GABAergic and regulatory signaling, with reported effects on the expression of GABA-related and neurotrophic genes. This regulatory emphasis distinguishes it from Semax's neurotrophic focus. The work is preclinical and does not demonstrate outcomes in people.
How is Selank different from Semax?: Both are Pro-Gly-Pro-stabilized heptapeptide analogs, but Selank (from tuftsin) is studied for GABAergic/regulatory signaling, while Semax (from an ACTH fragment) is studied for neurotrophic/BDNF activity. They act on different pathways and are studied as complementary research tools.

Sources and further reading#

PubMed — Selank tuftsin analog GABA / anxiolytic research: primary literature on the Selank neuropeptide.

For research use only. Not for human consumption, diagnosis, treatment, or prevention of any disease. All products are intended solely for laboratory research purposes.

Last updated: 2026-05-27